Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the marketing of a Class 1 new drug independently developed by the company. Approved indications: This product can be used in combination with a low-fat diet and other fat-lowering drugs to treat homozygous familial hypercholesterolemia (HoFH) in adults and adolescents 12 years and older to reduce low density lipoprotein cholesterol (LDL-C) levels.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.